CLINICAL EVALUATION OF THE EFFECTIVENESS OF “DR MICHAELS®” (ALSO BRANDED AS SORATINEX®) PRODUCTS IN THE TOPICAL TREATMENT OF PATIENTS WITH PLAQUE PSORIASIS

M. FIORANELLI¹, J. HERCOGOVÁ², ³, S. GIANFALDONI⁴, A.A.CHOKOEVA⁵, ⁶, G. TCHERNEV⁷, U. WOLLINA⁸, M TIRANT⁹, F. NOVOTNY¹⁰, M.G. ROCCIA¹¹, G.K. MAXIMOV¹², K. FRANÇA¹³, ¹⁴ and T. LOTTI¹⁵

¹Department of Nuclear Physics, Sub-nuclear and Radiation, Guglielmo Marconi University, Rome, Italy; ²2nd Medical Faculty, Charles University, Bulovka Hospital, Prague, Czech Republic; ³Institute of Clinical and Experimental Medicine, Prague, Czech Republic; ⁴Dermatological Department University of Pisa, Pisa, Italy; ⁵“Onkoderna” - Policlinic for dermatology and dermatologic surgery, Sofia, Bulgaria; ⁶Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria; ⁷Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria; ⁸Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany; ⁹Psoriasis & Skin Clinic, Melbourne, Australia; ¹⁰PRO SANUM Ltd, Saratorium of Prof. Novotny, Štěpánská Prague 1, Czech Republic; ¹¹University B.I.S. Group of Institutions, Punjab Technical University, Punjab, India; ¹²Department ‘Medicinal Information and Non-interventional studies’, Bulgarian Drug Agency, Sofia, Bulgaria; ¹³Department of Dermatology & Cutaneous Surgery, Department of Psychiatry & Behavioral Sciences, Institute for Bioethics & Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; ¹⁴Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi “G. Marconi”, Rome, Italy; ¹⁵Chair of Dermatology, University of Rome “G. Marconi” Rome, Italy

Psoriasis is generally considered as an autoimmune inflammatory cutaneous-systemic disease, with chronic course and high rate of recurrence, while its high risk of comorbidities affect the patients’ quality of life significantly. Despite the good therapeutic response, most of the available options show tendency for poor tolerance and high rate of occurrence of side effects. Therefore, the interest of patients and doctors to investigate the possibility of treating psoriasis with natural substances is not surprising. The aim of this study was to investigate the efficacy and safety of the herbal skin-care product Dr Michaels® (Soratinex®) for the management of chronic plaque psoriasis, within a 6 to 8 week treatment course. Thirty patients of both sexes, aged between 24 and 70 years with mild to moderate psoriasis vulgaris were included in this study. The products of Dr Michaels® (Soratinex®) were applied in sequence: cleansing gel, ointment after 3–4 minutes and tonic care (for the fire-smereared ointment) 2 times per day for restorative care and cleansing gel for psoriasis within scalp 3 times a week. The study lasted six weeks. The severity and extent of the lesions were evaluated by PASI score (Psoriasis Area and Severity Index). Based on the obtained result, the products of “Dr Michaels® (Soratinex®)” have proved to be effective in the treatment of mild and moderate psoriasis vulgaris. In the study group, no improvement was observed in 10% of patients, a slight improvement in 20%. good in 40% and very good in 16.6% of patients.